Cowen & Co. analyst Boris Peaker maintained a Hold rating on Seattle Genetics (SGEN) today and set a price target of $80. The company’s shares closed yesterday at $63.99.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 3.4% and a 41.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Seattle Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $76.71.
See today’s analyst top recommended stocks >>
Based on Seattle Genetics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.33 million. In comparison, last year the company had a net profit of $76.27 million.
Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGEN in relation to earlier this year. Last month, Vaughn Himes, the CTO of SGEN bought 4,704 shares for a total of $199,970.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers.
